Solid Biosciences Announces Closing of Acquisition of AavantiBio and Concurrent $75 Million Private Placement
CHARLESTOWN, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced the results of the special meeting of the stockholders held on December 1, 2022. At the special meeting, Solid’s stockholders voted in favor of all proposals, including the proposal to issue shares of Solid’s common stock to stockholders of AavantiBio in connection with the acquisition of AavantiBio pursuant to the agreement and plan of merger dated September 29, 2022 (the “Merger Agreement”) and to certain institutional investors in connection with a concurrent $75 million private placement. AavantiBio, Inc. is a privately held gene therapy company focused on transforming the lives of patients with Friedreich’s ataxia and rare cardiomyopathies.
En route to entering the clinic with its first AAV-based gene therapy for a rare neuromuscular disease, AavantiBio has let go of 30 employees, Endpoints News has learned.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--AavantiBio (“the Company”), a gene therapy company focused on transforming the lives of patients with rare genetic diseases, today announced the formation of its Scientific Advisory Board (SAB) and its members. The newly formed SAB will collaborate closely with AavantiBio’s senior leadership team and support the advancement of the Company’s diversified pipeline of gene therapy programs targeting rare genetic diseases with significant unmet medical need.
AavantiBio has poached another bluebird bio leader to bring its lead gene therapy program into clinical trials. Bluebird's vice president of preclinical and translational development is leaving to become chief scientific officer of the one-year-old biotech.
AavantiBio, a gene therapy company focused on transforming the lives of patients with rare genetic diseases, and Aldevron, active in the custom development and manufacture of plasmid DNA, proteins and mRNA for the biotech industry, formed a long-term partnership for the supply of plasmid DNA that will enable AavantiBio to advance its platform of innovative gene transfer therapies.
AavantiBio, a gene therapy company focused on transforming the lives of patients with rare genetic diseases, and Aldevron, a global leader in the custom development and manufacture of plasmid DNA, proteins and mRNA for the biotech industry, today announced a long-term strategic partnership for the supply of plasmid DNA that will enable AavantiBio to advance its platform of innovative gene transfer therapies.
AavantiBio and Resilience have announced a collaboration to manufacture a pipeline of therapies, including AavantiBio’s Friedreich’s Ataxia program, the company announced Thursday.
Catalent announced on April 27, 2021 that it has entered into a partnership with AavantiBio, a US-based gene therapy company, to support the development of AavantiBio’s gene therapies, including its lead program in Friedreich’s Ataxia (FA), a genetic disease caused by low levels of the protein frataxin due to mutations in the FXN gene.